Hypoallergenic Forms of the Ryegrass Pollen Allergen Lol p 5 as Candidates for Immunotherapy
暂无分享,去创建一个
R. Valenta | P. Bhalla | P. Valent | W. Sperr | I. Swoboda | S. Spitzauer | Mohan B. Singh | H. Fiebig | C. Ebner | V. Niederberger | H. Kahlert | Nicole A de Weerd
[1] R. Valenta,et al. Genetically Engineered and Synthetic Allergen Derivatives: Candidates for Vaccination against Type I Allergy , 1999, Biological chemistry.
[2] P. Bhalla,et al. Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity , 1999, International Archives of Allergy and Immunology.
[3] J. Lidholm,et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy , 1999, European journal of immunology.
[4] M. Schlaak,et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. , 1999, Journal of immunology.
[5] J Bousquet,et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.
[6] J. McCluskey,et al. Molecular basis of IgE-recognition of Lol p 5, a major allergen of rye-grass pollen. , 1998, Molecular immunology.
[7] J. McCluskey,et al. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. , 1996, The Journal of allergy and clinical immunology.
[8] D. Umetsu,et al. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type , 1995, The Journal of experimental medicine.
[9] R. Cooke,et al. SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER) , 1935, The Journal of experimental medicine.